Literature DB >> 21239811

Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation.

Nina Shah1, Sagar Lonial.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21239811      PMCID： PMC4086196          DOI： 10.1182/asheducation-2010.1.310

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN： 1520-4383


× No keyword cloud information.
  42 in total

1.  The role of second autografts in the management of myeloma at first relapse.

Authors:  Caroline L Alvares; Faith E Davies; Clive Horton; Gita Patel; Ray Powles; Gareth J Morgan
Journal:  Haematologica       Date:  2006-01       Impact factor: 9.941

2.  Low dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients.

Authors:  S Ciolli; F Leoni; F Gigli; L Rigacci; A Bosi
Journal:  Leuk Lymphoma       Date:  2006-01

3.  Prolonged overall survival with second on-demand autologous transplant in multiple myeloma.

Authors:  Francesca Elice; Roberto Raimondi; Alberto Tosetto; Anna D'Emilio; Eros Di Bona; Andrea Piccin; Francesco Rodeghiero
Journal:  Am J Hematol       Date:  2006-06       Impact factor: 10.047

4.  Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.

Authors:  Antonio Palumbo; Maria Teresa Ambrosini; Giulia Benevolo; Patrizia Pregno; Norbert Pescosta; Vincenzo Callea; Clotilde Cangialosi; Tommaso Caravita; Fortunato Morabito; Pellegrino Musto; Sara Bringhen; Patrizia Falco; Ilaria Avonto; Federica Cavallo; Mario Boccadoro
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

5.  Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy.

Authors:  R Baz; E Walker; M A Karam; T K Choueiri; R A Jawde; K Bruening; J Reed; B Faiman; Y Ellis; C Brand; G Srkalovic; S Andresen; R Knight; J Zeldis; M A Hussein
Journal:  Ann Oncol       Date:  2006-09-15       Impact factor: 32.976

6.  Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma.

Authors:  Muzaffar H Qazilbash; Rima Saliba; Marcos De Lima; Chitra Hosing; Daniel Couriel; Ana Aleman; Linda Roden; Richard Champlin; Sergio A Giralt
Journal:  Cancer       Date:  2006-03-01       Impact factor: 6.860

7.  A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.

Authors:  Paul G Richardson; Emily Blood; Constantine S Mitsiades; Sundar Jagannath; Steven R Zeldenrust; Melissa Alsina; Robert L Schlossman; S Vincent Rajkumar; K Raman Desikan; Teru Hideshima; Nikhil C Munshi; Kathleen Kelly-Colson; Deborah Doss; Mary L McKenney; Svetlana Gorelik; Diane Warren; Andrea Freeman; Rebecca Rich; Anfang Wu; Marta Olesnyckyj; Kenton Wride; William S Dalton; Jerome Zeldis; Robert Knight; Edie Weller; Kenneth C Anderson
Journal:  Blood       Date:  2006-07-13       Impact factor: 22.113

8.  Second autologous transplantation for multiple myeloma patients relapsing after the first autograft -- a pilot study for the evaluation of experimental maintenance therapies. Report of the prospective non-randomized pilot study of the Czech Myeloma Group.

Authors:  A Krivanová; R Hájek; M Krejcí; V Scudla; K Indrák; J Bacovský; T Büchler; A Svobodník; Z Adam; J Mayer; J Vorlícek
Journal:  Onkologie       Date:  2004-06

9.  A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

Authors:  S Jagannath; B Barlogie; J Berenson; D Siegel; D Irwin; P G Richardson; R Niesvizky; R Alexanian; S A Limentani; M Alsina; J Adams; M Kauffman; D-L Esseltine; D P Schenkein; K C Anderson
Journal:  Br J Haematol       Date:  2004-10       Impact factor: 6.998

10.  A phase 2 study of bortezomib in relapsed, refractory myeloma.

Authors:  Paul G Richardson; Bart Barlogie; James Berenson; Seema Singhal; Sundar Jagannath; David Irwin; S Vincent Rajkumar; Gordan Srkalovic; Melissa Alsina; Raymond Alexanian; David Siegel; Robert Z Orlowski; David Kuter; Steven A Limentani; Stephanie Lee; Teru Hideshima; Dixie-Lee Esseltine; Michael Kauffman; Julian Adams; David P Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245
View more
  5 in total

Review 1.  Applications and perspectives of nanomaterials in novel vaccine development.

Authors:  Yingbin Shen; Tianyao Hao; Shiyi Ou; Churan Hu; Long Chen
Journal:  Medchemcomm       Date:  2017-10-17       Impact factor: 3.597

2.  The immune microenvironment of myeloma.

Authors:  Kimberly Noonan; Ivan Borrello
Journal:  Cancer Microenviron       Date:  2011-08-25

3.  Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey.

Authors:  S Acaster; S Gaugris; G Velikova; K Yong; A J Lloyd
Journal:  Support Care Cancer       Date:  2012-08-12       Impact factor: 3.603

Review 4.  European perspective on multiple myeloma treatment strategies: update following recent congresses.

Authors:  Heinz Ludwig; Hervé Avet-Loiseau; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; Michele Cavo; Faith Davies; Javier de la Rubia; Sosana Delimpasi; Meletios Dimopoulos; Johannes Drach; Hermann Einsele; Thierry Facon; Hartmut Goldschmidt; Urs Hess; Ulf-Henrik Mellqvist; Philippe Moreau; Jesús San-Miguel; Pia Sondergeld; Pieter Sonneveld; Miklos Udvardy; Antonio Palumbo
Journal:  Oncologist       Date:  2012-05-09

5.  Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.

Authors:  Silvia Mangiacavalli; Lara Pochintesta; Cristiana Pascutto; Federica Cocito; Alessandra Pompa; Mario Cazzola; Alessandro Corso
Journal:  Am J Hematol       Date:  2012-12-08       Impact factor: 10.047
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.